These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 31376097)

  • 1. Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer.
    Carbone F; Grossi F; Bonaventura A; Vecchié A; Minetti S; Bardi N; Elia E; Ansaldo AM; Ferrara D; Rijavec E; Dal Bello MG; Biello F; Rossi G; Tagliamento M; Alama A; Coco S; Spallarossa P; Dallegri F; Genova C; Montecucco F
    Clin Exp Metastasis; 2019 Oct; 36(5):449-456. PubMed ID: 31376097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma.
    Noguchi G; Nakaigawa N; Umemoto S; Kobayashi K; Shibata Y; Tsutsumi S; Yasui M; Ohtake S; Suzuki T; Osaka K; Muraoka K; Hasumi H; Kondo K; Igarashi Y; Sasada T; Kishida T; Yao M
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):75-85. PubMed ID: 32537714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
    Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
    Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment.
    Bonaventura A; Grossi F; Carbone F; Vecchié A; Minetti S; Bardi N; Elia E; Ansaldo AM; Ferrara D; Rijavec E; Dal Bello MG; Rossi G; Biello F; Tagliamento M; Alama A; Coco S; Spallarossa P; Dallegri F; Genova C; Montecucco F
    Clin Transl Oncol; 2020 Sep; 22(9):1603-1610. PubMed ID: 32048158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
    Morita R; Okishio K; Shimizu J; Saito H; Sakai H; Kim YH; Hataji O; Yomota M; Nishio M; Aoe K; Kanai O; Kumagai T; Kibata K; Tsukamoto H; Oizumi S; Fujimoto D; Tanaka H; Mizuno K; Masuda T; Kozuki T; Haku T; Suzuki H; Okamoto I; Hoshiyama H; Ueda J; Ohe Y
    Lung Cancer; 2020 Feb; 140():8-18. PubMed ID: 31838169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
    Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
    Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
    Akamine T; Takada K; Toyokawa G; Kinoshita F; Matsubara T; Kozuma Y; Haratake N; Takamori S; Hirai F; Tagawa T; Okamoto T; Yoneshima Y; Okamoto I; Shimokawa M; Oda Y; Nakanishi Y; Maehara Y
    Surg Oncol; 2018 Mar; 27(1):88-94. PubMed ID: 29549910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status.
    Adachi Y; Tamiya A; Taniguchi Y; Enomoto T; Azuma K; Kouno S; Inagaki Y; Saijo N; Okishio K; Atagi S
    Cancer Med; 2020 Feb; 9(4):1383-1391. PubMed ID: 31880861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.
    Takeda T; Takeuchi M; Saitoh M; Takeda S
    Thorac Cancer; 2018 Oct; 9(10):1291-1299. PubMed ID: 30126063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.
    Shiroyama T; Suzuki H; Tamiya M; Tamiya A; Tanaka A; Okamoto N; Nakahama K; Taniguchi Y; Isa SI; Inoue T; Imamura F; Atagi S; Hirashima T
    Cancer Med; 2018 Jan; 7(1):13-20. PubMed ID: 29150906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
    Dudnik E; Moskovitz M; Daher S; Shamai S; Hanovich E; Grubstein A; Shochat T; Wollner M; Bar J; Merimsky O; Zer A; Goldstein DA; Hammerman A; Cyjon A; Shechtman Y; Abu-Amna M; Flex D; Roisman LC; Peled N;
    Lung Cancer; 2018 Dec; 126():217-223. PubMed ID: 29254746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab.
    Agulló-Ortuño MT; Gómez-Martín Ó; Ponce S; Iglesias L; Ojeda L; Ferrer I; García-Ruiz I; Paz-Ares L; Pardo-Marqués V
    Clin Lung Cancer; 2020 Jan; 21(1):75-85. PubMed ID: 31562055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer.
    Tamiya A; Tamiya M; Go H; Inoue T; Kunimasa K; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Suzuki H; Hirashima T; Atagi S; Shintani A; Imamura F
    Anticancer Res; 2020 Aug; 40(8):4229-4236. PubMed ID: 32727749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
    Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
    BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of the C-reactive protein:albumin ratio in non-small cell lung cancer patients treated with nivolumab.
    Araki T; Tateishi K; Sonehara K; Hirota S; Komatsu M; Yamamoto M; Kanda S; Kuraishi H; Hanaoka M; Koizumi T
    Thorac Cancer; 2021 Mar; 12(5):603-612. PubMed ID: 33434414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.
    Blasberg JD; Pass HI; Goparaju CM; Flores RM; Lee S; Donington JS
    J Clin Oncol; 2010 Feb; 28(6):936-41. PubMed ID: 20085934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.
    Basak EA; Koolen SLW; Hurkmans DP; Schreurs MWJ; Bins S; Oomen-de Hoop E; Wijkhuijs AJM; Besten ID; Sleijfer S; Debets R; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ
    Eur J Cancer; 2019 Mar; 109():12-20. PubMed ID: 30654225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.
    Mack PC; Redman MW; Chansky K; Williamson SK; Farneth NC; Lara PN; Franklin WA; Le QT; Crowley JJ; Gandara DR;
    J Clin Oncol; 2008 Oct; 26(29):4771-6. PubMed ID: 18779603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.